ATE286892T1 - Hydroxam- und carbonsäurederivate mit mmp- und tnf-hemmender aktivität - Google Patents

Hydroxam- und carbonsäurederivate mit mmp- und tnf-hemmender aktivität

Info

Publication number
ATE286892T1
ATE286892T1 AT98952928T AT98952928T ATE286892T1 AT E286892 T1 ATE286892 T1 AT E286892T1 AT 98952928 T AT98952928 T AT 98952928T AT 98952928 T AT98952928 T AT 98952928T AT E286892 T1 ATE286892 T1 AT E286892T1
Authority
AT
Austria
Prior art keywords
mmp
hydroxam
carboxylic acid
acid derivatives
inhibiting activity
Prior art date
Application number
AT98952928T
Other languages
English (en)
Inventor
Andrew Douglas Darwin D Baxter
David Alan Darwin Owen
John Gary Darwin Montana
Elisabeth Jane Reed Nicholson
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9723904.0A external-priority patent/GB9723904D0/en
Priority claimed from GBGB9814043.7A external-priority patent/GB9814043D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Application granted granted Critical
Publication of ATE286892T1 publication Critical patent/ATE286892T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT98952928T 1997-11-12 1998-11-12 Hydroxam- und carbonsäurederivate mit mmp- und tnf-hemmender aktivität ATE286892T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9723904.0A GB9723904D0 (en) 1997-11-12 1997-11-12 Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
GBGB9814043.7A GB9814043D0 (en) 1998-06-29 1998-06-29 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
PCT/GB1998/003396 WO1999024419A1 (en) 1997-11-12 1998-11-12 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity

Publications (1)

Publication Number Publication Date
ATE286892T1 true ATE286892T1 (de) 2005-01-15

Family

ID=26312587

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98952928T ATE286892T1 (de) 1997-11-12 1998-11-12 Hydroxam- und carbonsäurederivate mit mmp- und tnf-hemmender aktivität

Country Status (8)

Country Link
US (1) US6310088B1 (de)
EP (1) EP1030851B1 (de)
JP (1) JP2001522843A (de)
AT (1) ATE286892T1 (de)
AU (1) AU746158B2 (de)
CA (1) CA2308361A1 (de)
DE (1) DE69828638T2 (de)
WO (1) WO1999024419A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699899B1 (en) * 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
DK2041181T3 (da) * 2006-06-08 2011-08-29 Helmholtz Zentrum Muenchen Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
BRPI0811651A2 (pt) * 2007-05-18 2014-11-11 Inhibox Ltd Composto, composição farmacêutica, métodos para preparar uma composição farmacêutica, para tratar uma doença, distúrbio ou condição, para inibir a tace em uma célula, in vitro ou in vivo, e de regular (por exemplo, inibir) a liberação da citocina (por exemplo, a liberação da tnf-alfa) em uma célula, in vitro ou in vivo, uso de um composto, e, kit

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK123102B (da) * 1968-08-15 1972-05-15 Parke Davis & Co Analogifremgangsmåde til fremstilling af racemiske eller optisk aktive benzo[b]thiopheneddikesyreforbindelser eller carboxylatsalte deraf.
US3558655A (en) 1969-06-25 1971-01-26 Parke Davis & Co Benzo(b)thiopheneacetic acid compounds
US3770733A (en) 1971-08-30 1973-11-06 Pharmac Co Recordati Sa Chem C Novel therapeutically active dihydrobenzothiazine-s-dioxides and processes for preparing them
US4129655A (en) * 1976-04-26 1978-12-12 Ciba-Geigy Corporation Neuroleptic 2-piperidinoalkyl-1,4-benzodioxans
JPS6018659B2 (ja) * 1976-01-01 1985-05-11 協和醗酵工業株式会社 新規なベンゾフラン誘導体
GB2056441B (en) * 1979-07-26 1983-07-06 Kyowa Hakko Kogyo Kk Derivatives of benzo(b)furan and pharmaceutical compositions containing them
US4224330A (en) * 1979-09-13 1980-09-23 Zoecon Corporation Esters and thiolesters of benzothienyl acids
EP0350163A3 (de) * 1988-06-09 1990-11-22 Beecham Group Plc Renin inhibierende Peptide
JPH02250831A (ja) * 1989-03-23 1990-10-08 Kuraray Co Ltd ３，４―ジヒドロ―２ｈ―ベンゾピラン誘導体及びそれを有効成分とする抗消化性潰瘍剤
TW199152B (de) * 1990-11-01 1993-02-01 Takeda Pharm Industry Co Ltd
AU3899193A (en) * 1992-04-07 1993-11-08 British Bio-Technology Limited Hydroxamic acid based collagenase and cytokine inhibitors
GB9609794D0 (en) * 1996-05-10 1996-07-17 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
AU1047099A (en) 1999-05-31
EP1030851A1 (de) 2000-08-30
US6310088B1 (en) 2001-10-30
EP1030851B1 (de) 2005-01-12
DE69828638T2 (de) 2005-12-01
DE69828638D1 (de) 2005-02-17
CA2308361A1 (en) 1999-05-20
AU746158B2 (en) 2002-04-18
JP2001522843A (ja) 2001-11-20
WO1999024419A1 (en) 1999-05-20

Similar Documents

Publication Publication Date Title
NO20002440D0 (no) Hydroksam- og karboksylsyrederivater med MMP- og TNF- inhiberende aktivitet
GB9801690D0 (en) Therapeutic agents
DE50010931D1 (de) Substituierte benzimidazole
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
PT841929E (pt) Quinolonas e sua utilizacao terapeutica
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
ATE290382T1 (de) Heterozyklische kalium-kanal inhibitoren
ATE302606T1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
DE59709414D1 (de) Oxyiminopregnancarbolactone
EP0932606A4 (de) Prenyl-transferase inhibitoren
DE69808099D1 (de) Substituierte 6-alkylphenanthridine
ATE286892T1 (de) Hydroxam- und carbonsäurederivate mit mmp- und tnf-hemmender aktivität
ATE172721T1 (de) Aminosäurederivate und ihre verwendung als enkephalinase-inhibitoren
ATE286395T1 (de) Antithrombotische mittel
GB9723905D0 (en) Heterocyclic compounds having MMP and TNF inhibitory activity
PT1104419E (pt) Derivados de azabicicloheptano substituidos no azoto sua preparacao e utilizacao
HUP0002727A2 (hu) Eljárás fibrinogén csökkentésére benzotiofénszármazékok felhasználásával
DK0832085T3 (da) Phosphinsyrederivater med metallopeptidaseinhiberende aktivitet
DK0937075T3 (da) Hidtil ukendte imidazo- og oxazolopyridiner som phosphodiesteraseinhibitorer
SU1783774A1 (ru) Натриевая соль n-(3-хлорбутен-2-ил)антраниловой кислоты, проявляющая противовоспалительную и анальгетическую активность
SU1732642A1 (ru) 4-хлоранилид n-ацетил-n-аллилантраниловой кислоты, проявляющий противовоспалительную и анальгетическую активность
SU1549026A1 (ru) 4-Карбэтокси-4-(2-п-толиламинотиазолил-4)-гексановая кислота, проявляющая противовоспалительную активность

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties